Literature DB >> 2660360

T cell depletion of human bone marrow. Comparison of Campath-1 plus complement, anti-T cell ricin A chain immunotoxin, and soybean agglutinin alone or in combination with sheep erythrocytes or immunomagnetic beads.

J N Frame1, N H Collins, T Cartagena, H Waldmann, R J O'Reilly, B Dupont, N A Kernan.   

Abstract

The aim of this study was to compare the extent of in vitro T cell depletion and recovery of hematopoietic progenitor cells achieved with five methods of T cell depletion. Bone marrow samples from the same source were treated with monoclonal antibody Campath-1 (CP1) and human complement, XomaZyme-H65 (anti-T cell ricin A chain immunotoxin), or soybean agglutinin (SBA) alone or in combination with sheep erythrocytes (EAET) or a cocktail of immunomagnetic beads (B) directly coated with anti-CD2, anti-CD3, or anti-CD8 monoclonal antibodies. Residual T cells were enumerated by limiting dilution analysis, EAET rosetting, and proliferative responses to phytohemagglutinin. The results of this study demonstrated the following reductions in BM T cells as detected by limiting dilution analysis (mean % control): SBA+B (99.9%), SBA+EAET (99.8%), CP1+C' (99.4%), anti-T cell ricin A chain immunotoxin (99.0%), and SBA alone (94.2%). Neither PHA response nor enumeration of residual EAET rosettes provided discriminating differences in the degree of T cell depletion by treatment method when T cell reductions exceeded 99.0% by LDA. These results demonstrate the ability of CP1+C', XomaZyme-H65, and SBA plus sheep erythrocyte or magnetic bead depletion to achieve a greater than 99% reduction of BM T cells and the importance of limiting dilution analysis in defining differences in T cell numbers when depletion exceeded 99%.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2660360     DOI: 10.1097/00007890-198906000-00013

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

Review 1.  Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.

Authors:  Richard J O'Reilly; Tao Dao; Guenther Koehne; David Scheinberg; Ekaterina Doubrovina
Journal:  Semin Immunol       Date:  2010-05-26       Impact factor: 11.130

Review 2.  Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation.

Authors:  Betty Ky Hamilton
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 3.  Novel approaches in allogeneic stem cell transplantation.

Authors:  Esperanza B Papadopoulos; Ann A Jakubowski
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

Review 4.  T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells.

Authors:  R J O'Reilly; G Koehne; A N Hasan; E Doubrovina; S Prockop
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

5.  The use of soybean agglutinin (SBA) for bone marrow (BM) purging and hematopoietic progenitor cell enrichment in clinical bone-marrow transplantation.

Authors:  A Nagler; S Morecki; S Slavin
Journal:  Mol Biotechnol       Date:  1999-04       Impact factor: 2.695

6.  Newly established human pancreatic carcinoma cell lines and their lectin binding properties.

Authors:  N Nishimura; S Saito; Y Kubota; N Moto-o; K Taguchi; K Yamazaki; A Watanabe; H Sasaki
Journal:  Int J Pancreatol       Date:  1993-02

Review 7.  Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future.

Authors:  A Saad; L S Lamb
Journal:  Bone Marrow Transplant       Date:  2017-03-20       Impact factor: 5.483

Review 8.  Role of αβ T Cell Depletion in Prevention of Graft versus Host Disease.

Authors:  Haitham Abdelhakim; Hisham Abdel-Azim; Ayman Saad
Journal:  Biomedicines       Date:  2017-06-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.